^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    7d
    Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA) (2024-517279-20-02)
    P1/2, N=40, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    CASH: Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (clinicaltrials.gov)
    P3, N=630, Recruiting, Centre Hospitalier St Anne | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (clinicaltrials.gov)
    P2, N=480, Recruiting, Verona Pharma plc | Trial completion date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    14d
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    14d
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd. | Trial completion date: Aug 2025 --> Aug 2026
    Trial completion date
    16d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    28d
    MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and are Clinically Relevant Across Central Nervous System Disorders. (PubMed, Cancer Res)
    The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases, and possibly other brain disorders.
    Journal
    |
    CD74 (CD74 Molecule) • IFNG (Interferon, gamma)
    |
    Eyevinal (ibudilast)
    28d
    TNX-103-07: LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (2025-522475-28-00)
    P2/3, N=116, Not yet recruiting, Tenax Therapeutics Inc.
    New P2/3 trial
    1m
    LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (clinicaltrials.gov)
    P3, N=540, Recruiting, Tenax Therapeutics, Inc. | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    1m
    Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P3, N=800, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    1m
    Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage (clinicaltrials.gov)
    P2, N=100, Recruiting, National Taiwan University Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: May 2027 --> Jan 2027
    Enrollment open • Trial primary completion date
    2ms
    COMBAT-ALS: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (clinicaltrials.gov)
    P2/3, N=234, Active, not recruiting, MediciNova | Trial completion date: Dec 2026 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)